Related Experiment Video
Updated: Apr 17, 2026
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.3K
Association between some inflammatory markers and primary ovarian insufficiency
Gülçin Yldrm1, Aytekin Tokmak, Mahmut Kuntay Kokanal
11Department of Obstetrics and Gynecology, Dr. Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey 2Department of Biochemistry, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Menopause (New York, N.Y.)
|February 4, 2015
Summary
Neutrophil-to-lymphocyte ratio (NLR) is a promising biomarker for primary ovarian insufficiency (POI). Lower NLR levels may indicate POI, aiding in early diagnosis and fertility treatment strategies.
Area of Science:
- Reproductive Endocrinology
- Clinical Immunology
- Hematology
Background:
- Primary ovarian insufficiency (POI) affects women of reproductive age, leading to infertility.
- Biomarkers for early POI detection are crucial for timely intervention and fertility management.
Purpose of the Study:
- To evaluate the diagnostic value of neutrophil-to-lymphocyte ratio (NLR), serum amyloid A protein (SAA), and C-reactive protein (CRP) in primary ovarian insufficiency (POI).
Main Methods:
- A comparative cross-sectional study included 84 women (43 with POI, 41 controls).
- Clinical, demographic, and laboratory data including NLR, SAA, and CRP levels were analyzed.
- Receiver operating characteristic (ROC) and multivariate logistic regression analyses were performed.
Main Results:
- NLR was significantly lower in women with POI compared to controls (P < 0.001).
- SAA and CRP levels did not significantly differ between the groups (P > 0.05).
- ROC analysis identified NLR as a significant discriminator for POI (AUC = 0.829), while SAA and CRP were not.
Conclusions:
- NLR shows potential as a promising biomarker for early detection of POI.
- SAA and CRP are not effective discriminative markers for POI.
- NLR may assist in developing targeted fertility treatment options for women with POI.
